MedTrace Logo

Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer

NCT00782041 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2009-09-15

No results posted yet for this study

Summary

Primary:

* To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline.

Secondary:

* To assess the safety and tolerability of oxaliplatin
* To assess time to progression and overall survival.

Conditions

  • Uterine Neoplasms

Interventions

DRUG

Oxaliplatin

85 mg/m²

DRUG

5-FluoroUracil

2,000 mg/m²

DRUG

Folinic acid

20 mg/m²

Sponsors & Collaborators

Principal Investigators

  • Paibulsirijit Sompob, MD · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2003-08-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00782041 on ClinicalTrials.gov